scholarly journals Case Report: A Case of Pituitary Adenoma Producing Growth Hormone and Thyroid-Stimulating Hormone Simultaneously

2021 ◽  
Vol 12 ◽  
Author(s):  
Junpei Sanada ◽  
Fuminori Tatsumi ◽  
Shinji Kamei ◽  
Yoshiro Fushimi ◽  
Masashi Shimoda ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Pituitary Adenoma ◽  
Thyroid Function ◽  
Tumor Resection ◽  
Brain Magnetic Resonance Imaging ◽  
Thyroid Stimulating Hormone ◽  
Clinical Findings ◽  
Additional Treatment ◽  
Pituitary Fossa ◽  
Stimulating Hormone

BackgroundPituitary adenoma producing growth hormone (GH) or thyroid-stimulating hormone (TSH) is characterized by various specific symptoms and/or findings. However, the frequency of pituitary adenoma producing both hormones is relatively low. In this report, we show a case of pituitary adenoma producing both GH and TSH simultaneously.Case presentationA 27-year-old woman was diagnosed as acromegaly based on various symptoms and clinical findings. For further examination and treatment, she was hospitalized in our institution. It was likely that this subject had pituitary adenoma producing both GH and TSH. In brain magnetic resonance imaging, there was a giant tumor around pituitary fossa. After the diagnosis of GH- and TSH-producing pituitary adenoma, pituitary tumor resection and cyber knife therapy were performed. In addition, we started additional treatment with somatostatin analog and GH receptor antagonist. After then, GH and insulin-like growth factor (IGF-1) levels were suppressed. After the operation, since thyroid function was not sufficiently suppressed, we started anti-thyroid drug thiamazole. After then, thyroid function was normalized and we stopped thiamazole. In GH and TSH staining, many GH-positive and TSH-positive cells were observed. These findings further confirmed our diagnosis that the pituitary adenoma in this subject produced both GH and TSH simultaneously.ConclusionsWe should bear in mind the possibility of pituitary adenoma producing both GH and TSH at the same time.

A RE-EXAMINATION OF THE TADPOLE IN METAMORPHIC STASIS AS A RECIPIENT IN A BIOASSAY FOR THYROID-STIMULATING HORMONE

1974 ◽  
Vol 61 (1) ◽  
pp. 15-19 ◽  
Author(s):  
MELVIN CHING
Keyword(s):  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Thyroid Function ◽  
Anterior Pituitary ◽  
Rana Pipiens ◽  
Thyroid Stimulating Hormone ◽  
Pituitary Extract ◽  
Metamorphic Stage ◽  
Stimulating Hormone

SUMMARY The tadpole, in metamorphic stasis, has been used as a bioassay recipient for thyroid-stimulating hormone (TSH). The validity of its use for this purpose, however, has not been tested critically, particularly with respect to the effect of other hormones, most notably, growth hormone (GH) and luteinizing hormone (LH). Growth hormone has been shown to influence thyroid function and LH is a common contaminant of pituitary TSH preparations. Tadpoles of Rana pipiens, arrested at a particular metamorphic stage, received various concentrations of LH alone, a combination of doses of GH and TSH, or GH and rat anterior pituitary extract. Growth hormone was ineffective in re-inducing metamorphosis in 78% of cases, whereas LH stimulated metamorphosis in the tadpoles.

scholarly journals Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tuo Deng ◽  
Wenwen Zhang ◽  
Yanling Zhang ◽  
Mengqi Zhang ◽  
Zhikun Huan ◽  
...  
Keyword(s):  
Thyroid Function ◽  
Thyroid Stimulating Hormone ◽  
Mrna Levels ◽  
Dependent Manner ◽  
Osteoblast Proliferation ◽  
Normal Thyroid ◽  
Normal Thyroid Function ◽  
Gene And Protein Expression ◽  
Proliferation And Differentiation ◽  
Stimulating Hormone

Abstract Background As the incidence of secretory osteoporosis has increased, bone loss, osteoporosis and their relationships with thyroid-stimulating hormone (TSH) have received increased attention. In this study, the role of TSH in bone metabolism and its possible underlying mechanisms were investigated. Methods We analyzed the serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and TSH and the bone mineral density (BMD) levels of 114 men with normal thyroid function. In addition, osteoblasts from rat calvarial samples were treated with different doses of TSH for different lengths of time. The related gene and protein expression levels were investigated. Results A comparison of the BMD between the high-level and low-level serum TSH groups showed that the TSH serum concentration was positively correlated with BMD. TSH at concentrations of 10 mU/mL and 100 mU/mL significantly increased the mRNA levels of ALP, COI1 and Runx2 compared with those of the control (P < 0.05, P < 0.01). Bone morphogenetic protein (BMP)2 activity was enhanced with both increased TSH concentration and increased time. The protein levels of Runx2 and osterix were increased in a dose-dependent manner. Conclusions The circulating concentrations of TSH and BMD were positively correlated with normal thyroid function in males. TSH promoted osteoblast proliferation and differentiation in rat primary osteoblasts.

scholarly journals Management of thyroid disease in pregnancy – Room for improvement in the first trimester

2016 ◽  
Vol 9 (3) ◽  
pp. 126-129 ◽  
Author(s):  
Helen Robinson ◽  
Philip Robinson ◽  
Michael D’Emden ◽  
Kassam Mahomed
Keyword(s):  
General Practitioner ◽  
Thyroid Function ◽  
Thyroid Disease ◽  
Thyroid Dysfunction ◽  
First Trimester ◽  
Antenatal Clinic ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Function Tests ◽  
In Pregnancy ◽  
Stimulating Hormone

Background First-trimester care of maternal thyroid dysfunction has previously been shown to be poor. This study evaluates early management of thyroid dysfunction in pregnancy in Australia. Methods Patients reviewed by the Obstetric Medicine team for thyroid dysfunction from 1 January 2012 to 30 June 2013 were included. Data were collected on gestation at referral from the patient’s general practitioner to the antenatal clinic, information provided in the referral letter, thyroid function tests and thyroid medications. Results Eighty-five women were included in the study. At the time of general practitioner referral to antenatal services, 19% of women with preexisting thyroid disease had no thyroid function tested. Forty-three percent had an abnormal thyroid-stimulating hormone defined as being outside the laboratory-specific pregnancy reference range if available, or outside the level of 0.1–2.5 mIu/L in the first trimester, 0.2–3.0 mIu/L in the second trimester and 0.3–3.0 mIu/L in the third trimester. Only 21% of women increased their thyroxine dose prior to their first antenatal clinic review. Conclusion This study highlights that a significant proportion of women with known thyroid disease either have untested thyroid function in the first trimester or a thyroid-stimulating hormone outside of levels recommended by guidelines.

Effect of 3,5-diiodo-L-thyronine on thyroid stimulating hormone and growth hormone serum levels in hypothyroid rats

Life Sciences ◽  
1998 ◽  
Vol 62 (26) ◽  
pp. 2369-2377 ◽  
Author(s):  
Maria Moreno ◽  
Assunta Lombardi ◽  
Pietro Lombardi ◽  
Fernando Goglia ◽  
Antonia Lanni
Keyword(s):  
Growth Hormone ◽  
Serum Levels ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone

scholarly journals Association of altered thyroid function and prolactin level in polycystic ovarian syndrome

2016 ◽  
Vol 45 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Marufa Mustari ◽  
MA Hasanat ◽  
Qamrul Hasan ◽  
Sadiqa Tuqan ◽  
Md Shah Emran ◽  
...  
Keyword(s):  
Thyroid Function ◽  
Prolactin Level ◽  
Polycystic Ovarian Syndrome ◽  
Density Lipoprotein ◽  
Serum Testosterone ◽  
Thyroid Stimulating Hormone ◽  
Primary Infertility ◽  
Altered Thyroid ◽  
Ovarian Syndrome ◽  
Stimulating Hormone

Polycystic ovarian syndrome (PCOS) is a common disorder for female with fertile age. Along with other clinical and biochemical manifestations, thyroid function and prolactin level may be altered in patients with PCOS. This study aimed to evaluate the clinical and biochemical status, as well as alteration of thyroid stimulating hormone (TSH), prolactin (PRL) level in patients with PCOS. Present study comprised of 100 diagnosed PCOS patients according to revised Rotterdem Consensus criteria. All patients were studied for serum testosterone, LH (lutenizing hormone), FSH (follicle stimulating hormone), blood glucose, lipid profile as well as TSH, FT4 (free thyroxin) and prolactin level. Out of 100 PCOS patients 97 had hirsutism, 64 had acanthosis nigricans, where menstrual irregularities were in 94 patients. Diastolic blood pressure (74±1.1 vs. 77±0.9, mmHg; p=0.017), total cholesterol (163±5.3 vs. 193±6.2 mg/dl; p<0.001), low density lipoprotein (LDL, 104±3.7 vs. 124±4.9 mg/dl; p=0.002) and frequency of acanthosis (25% vs. 75%; p<0.001) were significantly higher among the patients having BMI>25 Kg/m2 than those of have ? 25 Kg/m2. Among the fertile women (n=53), 47% had primary and 41.5% had secondary infertility; whereas of the total patients, 21% had altered thyroid function and 6.1% had raised prolactin (PRL, ng/ml) level. Differences of TSH (4.1±3.6 vs. 3.5±6.8, mIU/L; p=0.725) was not significant; whereas level of PRL (13.87±6.9vs. 9.4±5.2 ng/ml; p=0.018) was significantly higher in the group of primary infertility. Hirsutism, menstrual disturbance and acanthosis were very common in PCOS. Both primary and secondary sterility were also commonly observed and PRL was higher in primary infertility. About one fifth of PCOS had altered thyroid function.Bangladesh Med J. 2016 Jan; 45 (1): 1-5

Thyroid Function and Release of Thyroid-stimulating Hormone and Prolactin from the Pituitary in Human Obesity

1991 ◽  
Vol 19 (5) ◽  
pp. 389-394 ◽  
Author(s):  
R. Scaglione ◽  
M.R. Averna ◽  
M.A. Dichiara ◽  
C.M. Barbagallo ◽  
G. Mazzola ◽  
...  
Keyword(s):  
Thyroid Function ◽  
Thyroid Stimulating Hormone ◽  
Human Obesity ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document